VCs Are Pouring Billions into Biotech in 2018

Vcs Are Pouring Billions into Biotech

 

With tax reform in place and corporations expecting lower taxes and easier access to overseas cash, the biopharma industry focus has been on potential merger-and-acquisition activity. So far, the big deals have been Celgene acquiring Juno Therapeutics for $9 million and Impact Biomedicines for $7 billion, and then Sanofi US buying Bioverativ for $11.6 billion and then Ablynx for $4.8 billion. Then Seattle Genetics, Inc. acquired Cascadian Therapeutics (Formally known as Oncothyreon) for $614 million.

Read More